pharmaphorum

DECEMBER 15, 2020

During this time, the role and responsibility of generics suppliers and manufacturers has been brought into stark perspective as one of the leading contributors in this industry-wide effort. The pandemic has further highlighted how research is not strictly limited to large, “innovator” pharmaceutical companies.

Generic Medicine 93

Generic Medicine Pharmaceutical Companies Pharmaceutical Companies Vaccines 93

European Pharmaceutical Review

FEBRUARY 26, 2024

At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines. These products were designated as an orphan medicine during their development.

Generic Medicine 98

Generic Medicine Pharmaceutical Companies Pharmaceutical Companies Vaccines 98

pharmaphorum

MAY 26, 2022

Within pharma and healthcare, where greater representation has been proven to lead to better health outcomes for all patients and the pharmaceutical companies developing medicines, change is also happening. Vaccines approved for public use require comprehensive RCTs to establish their safety and efficacy.

Packaging 143

Packaging Vaccines Generic Medicine Compounding 143

European Pharmaceutical Review

FEBRUARY 20, 2025

The US imports a substantial volume of APIs and finished medicines, many of which are essential for patient care, meaning these tariffs could have far-reaching implications. 1 Here, we explore the potential impact of tariffs on pharmaceutical supply chains, pricing, investment and industry strategy.

Generic Medicine 20

Generic Medicine Hospitals Patient Care Vaccines 20